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OBJECTIVE — To determine A1C cut points for glucose intolerance in Asian Indians.
RESEARCH DESIGN AND METHODS — A total of 2,188 participants without known
diabetes were randomly selected from the Chennai Urban Rural Epidemiology Study. All had
fasting plasma glucose (FPG) and 2-h postload plasma glucose measurements after a 75-g load
and were classiﬁed as having impaired fasting glucose (IFG) (American Diabetes Association
[ADA]criteria,FPG5.5and7mmol/l,andWorldHealthOrganization[WHO]criteria,FPG
6.1and7mmol/l),impairedglucosetolerance(IGT)(2-hpostloadplasmaglucose7.8and
11.1 mmol/l), or diabetes (FPG 7 mmol/l and/or 2-h postload plasma glucose 11.1 mmol/
l). A1C was measured using the Bio-Rad Variant machine. Based on receiver operating charac-
teristic curves, optimum sensitivity and speciﬁcity were derived for deﬁning A1C cut points for
diabetes, IGT, and IFG.
RESULTS — Mean  SD values of A1C among subjects with normal glucose tolerance, IGT,
and diabetes were 5.5  0.4, 5.9  0.6, and 8.3  2.0%, respectively (Ptrend  0.001) with
considerable overlap. To identify diabetes based on 2-h postload plasma glucose, the A1C cut
point of 6.1% had an area under the curve (AUC) of 0.941 with 88.0% sensitivity and 87.9%
speciﬁcity. When diabetes was deﬁned as FPG 7.0 mmol/l, the A1C cut point was 6.4%
(AUC  0.966, sensitivity 93.3%, and speciﬁcity 92.3%). For IGT, AUC  0.708; for IFG,
AUC  0.632 (WHO criteria) and 0.708 (ADA criteria), and the A1C cut point was 5.6%.
CONCLUSIONS — In Asian Indians, A1C cut points of 6.1 and 6.4% deﬁned diabetes by
2-h postload plasma glucose or FPG criteria, respectively. A value of 5.6% optimally identiﬁed
IGT or IFG but was 70% accurate.
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A
1C is an indicator of the average
blood glucose concentrations over
the preceding 2–3 months and is
currently considered the best index of
metabolic control in individuals with di-
abetes (1). The Diabetes Control and
Complications Trial and the UK Prospec-
tive Diabetes Study (UKPDS) have dem-
onstrated that lowering A1C can reduce
theriskofdiabetesmicrovascularcompli-
cations (2,3). An association between
A1C and cardiovascular risk factors in
subjects with normal glucose tolerance
(NGT) was also reported (4).
Until recently, A1C had not been rec-
ommended as a diagnostic or a screening
tool because of several factors: lack of
standardization, low sensitivity, and high
cost(5).However,aftereffortstoimprove
standardization of the A1C assay and the
introduction of the new International
Federation of Clinical Chemists (IFCC)
standards, A1C is now being considered
fordiagnosticandscreeningpurposes(6).
A1C does not need to be measured in a
fasting state or with a glucose load and,
therefore,offerspotentialeaseandconve-
nience. A recent American Diabetes Asso-
ciation (ADA) International Expert
Committee proposed an A1C cut point of
6.5% as a diagnostic test for diabetes (7).
It is important to investigate whether
these cut points for A1C apply to all pop-
ulationsworldwide.Thenormativedistri-
bution for A1C levels has been described
in western populations in subjects with
NGT as well as those with impaired glu-
cose tolerance (IGT) (8). However, there
are no reports of the normative A1C dis-
tributions, to our knowledge, from India,
whichcurrentlyhasthelargestnumberof
individuals with diabetes in the world.
Here, we examine the distribution of A1C
in a south Indian population and explore
optimalcutpointsforidentifyingdiabetes
and high-risk pre-diabetic groups.
RESEARCH DESIGN AND
METHODS— The Chennai Urban
Rural Epidemiology Study (CURES) is a
cross-sectional population-based study
representative of Chennai (formerly Ma-
dras), the largest city in southern India,
with a population of 5 million people.
The details of CURES have been reported
previously(9).Inbrief,CURESwasbased
on the model of systematic stratiﬁed ran-
domsampling,wherein,forphase1ofthe
study, 46 of the 155 wards in Chennai
were selected for sampling, providing a
total sample size of 26,001 individuals
aged 20 years.
In a subsequent phase, every 10th
subject recruited in phase 1 (n  2,600)
was invited for detailed testing, including
an oral glucose tolerance test (OGTT) in
those without self-reported diabetes, and
the response rate was 90% (2,350 of
2,600 subjects) (Fig. 1). Anthropometric
measurements including weight, height,
and waist measurements were obtained
using standardized techniques (9). BMI
was calculated using the formula, weight
in kilograms divided by the square of
height in meters. Blood pressure was re-
corded in the sitting position in the right
arm to the nearest 2 mmHg with a mer-
cury sphygmomanometer (Diamond De-
luxe BP apparatus; Pune, India). Two
readings were taken 5 min apart, and the
mean of the two was used.
Fastingplasmaglucose(FPG)and2-h
postload (75-g) plasma glucose (glucose
oxidase-peroxidase method), serum cho-
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amidopyrinemethod)serumtriglycerides
(glycerol phosphate oxidase-peroxidase-
amidopyrine method), and HDL choles-
terol(directmethod,polyethyleneglycol-
pretreated enzymes) were measured
using a Hitachi-912 Autoanalyzer (Hita-
chi,Mannheim,Germany).Theintra-and
interassay coefﬁcients of variation (CVs)
for the biochemical assays ranged from
3.1 to 7.6%. LDL cholesterol was calcu-
lated using the Friedewald equation.
Of the 2,350 subjects who received
an OGTT, A1C was measured in 2,188
subjects (Response rate 93.1%). A1C was
measuredusingtheVariantmachine(Bio-
Rad Laboratories, Hercules, CA). Our
center participates in the Unity program
of Bio-Rad A1C standardization. The CV
for the A1C assay was 3.5%. The CV for
in-house quality control was 2.5%. In
the external quality assessment scheme,
bias for the A1C analysis was 1.75%, and
imprecision was 2.75%, indicating good
reproducibility.
Deﬁnitions and diagnostic criteria
Diabetes. Diabeteswasdiagnosedbased
on the World Health Organization
(WHO) Consulting Group Criteria (10),
i.e., FPG 126 mg/dl (7 mmol/l) and/or
2-h plasma glucose after an OGTT 200
mg/dl (11.1 mmol/l).
IGT. IGT was deﬁned as 2-h postload
plasma glucose 140 mg/dl (7.8 mmol/l)
and 200 mg/dl (11.1 mmol/l) by WHO
criteria (10).
Impaired fasting glucose. Impaired
fasting glucose (IFG) was deﬁned using
ADA criteria (11) if FPG was 100 mg/dl
(5.5 mmol/l) and 126 mg/dl (7 mmol/l)
and using WHO criteria (10) if FPG was
110 mg/dl (6.1mmol/l) and 126
mg/dl (7 mmol/l).
NGT. NGT was deﬁned as FPG 100
mg/dl (5.5 mmol/l) and 2-h postload
plasma glucose 140 mg/dl (7.8 mmol/l)
by WHO criteria (10).
Statistical analysis
Student’s t test or one-way ANOVA (with
the Tukey honestly signiﬁcant difference)
were used to compare groups for contin-
uous variables and the 
2 test or Fisher
exact test were used to compare propor-
tions. Receiver operating characteristic
curves were plotted using sensitivity and
1  speciﬁcity for different cut points of
A1C, taking the diagnosis of diabetes,
IGT, or IFG based on various plasma glu-
cose criteria as the gold standard. Sensi-
tivity was deﬁned by the proportion of
subjects with a given risk factor who were
identiﬁedcorrectlybyaA1Cvaluegreater
than or equal to the cut point. Speciﬁcity
was deﬁned by the proportion of subjects
without the risk factor who were identi-
ﬁed by a A1C value below the cut point.
The area under the curve was con-
structed, and by interpolation from the
area under the curve, the point closest to
the upper left-hand corner, which maxi-
mized sensitivity and speciﬁcity, was se-
lected as the optimal cut point; this
identiﬁed the highest number of subjects
with or without diabetes, IGT, or IFG
(12). Positive and negative predictive val-
ues and accuracy for predicting diabetes,
IGT,andIFGwerecalculatedfordifferent
cut points of A1C.
RESULTS— Among the 2,188 sub-
jects who had both OGTT and A1C tests,
1,710 (78.2%) had NGT, 258 (11.8%)
had IGT, and 220 (10.1%) had newly di-
agnosed diabetes (NDD). Subjects with
glucose intolerance (i.e., IGT or NDD)
were older than subjects with NGT (P 
0.01). Waist circumference, systolic and
diastolic blood pressure, FPG, 2-h post-
load plasma glucose, A1C, serum choles-
terol, serum triglyceride, and LDL
cholesterol were also higher among sub-
Figure 1—CURES methodology.
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NDD) than in those with NGT. Mean 
SD values of A1C among subjects with
NGT, IGT, and NDD were 5.5  0.4,
5.9  0.6, and 8.3  2.0%, respectively
(Ptrend  0.001) (Table 1).
As shown in Table 2, for diabetes, us-
ing the 2-h postload plasma glucose
200 mg/dl (11.1 mmol/l) criterion, the
A1C cut point of 6.1% had the highest
sensitivity and speciﬁcity. Using the FPG
126mg/dl(7.0mmol/l)criterionfordi-
abetes, the optimal A1C cut point was
6.4%andforthe2-hpostloadplasmaglu-
cose 200 mg/dl and FPG 126 mg/dl
criterion, the optimal A1C cut point was
6.5%. The accuracy of correctly differen-
tiatingapersonwithNDDselectedatran-
dom from the population varied from
90.2 to 95.9% (Table 2), depending on
the deﬁnition of diabetes and the respec-
tive cut point. For IGT, the optimal A1C
cut point was 5.6%. For IFG, deﬁned by
either the WHO criterion of FPG 110
(6.1 mmol/l) and 126 mg/dl (7.0
mmol/l) or the ADA criterion of FPG
100 mg/dl (5.6 mmol/l) and 126
mg/dl (7.0 mmol), the optimal A1C cut
point was 5.6%. The accuracy of identify-
ing these pre-diabetic states was 70%.
Figure 2 shows the distribution of
A1C in those with NGT, IGT, and diabe-
tes. It can be seen that there is consider-
able overlap among the three categories
with respect to the A1C levels. The per-
centageofsubjectswithNGT,IGTand/or
IFG,anddiabetesidentiﬁedusingvarious
A1CcutpointsisshowninTable3.Using
a cut point of 5.6%, 73.6% of those with
IGTand/orIFG(usingWHOcriteria)and
72.8% of subjects with IFG (using ADA
criteria)wouldbecorrectlyidentiﬁed.Us-
ing the cut point of 6.5%, 78.2% of sub-
jects with diabetes would bet correctly
identiﬁed; however, 19.4% of subjects
withIGTand/orIFG(usingADAcriteria),
18.1% of subjects with IGT and/or IFG
(using WHO criteria), and 3.0% of sub-
jects with NGT would be included in this
category.
CONCLUSIONS — Our population-
based data suggest that A1C cut points of
6.1 and 6.4% are optimal for identifying
NDD in Asian Indians by 2-h postload
plasma glucose and FPG criteria, respec-
tively. These cut points can identify sub-
jects with diabetes with 90% accuracy
in this population. In addition, our data
suggest that an A1C cut point of 5.6%
would identify subjects with IGT and/or
IFG with optimal speciﬁcity and sensitiv-
ity, but the accuracy is only 69–74%.
A large meta-analysis using data from
10 different studies concluded that a A1C
cut point of 7.0%, could identify diabetes
requiring pharmacological therapy (13).
A population-based study of 3,190 adults
of Malay ethnicity concluded that A1C
levels in the range 6.6–7% were optimal
for detecting microvascular complica-
tions (14). Studies have also demon-
strated that a A1C threshold of 6.0%
discriminates well between OGTT-
diagnosed diabetic and nondiabetic sub-
jects (15,16).
A recent report by an International
ExpertCommitteehasproposedthatadi-
agnosisofdiabetescanbemadeiftheA1C
level is 6.5%, but the diagnosis should
be conﬁrmed with a repeat A1C test, un-
less clinical symptoms or glucose levels
200 mg/dl (11.1 mmol/l) are present
(7). However, this decision was based on
Table 1—Clinical and biochemical characteristics of study subjects
NGT
Pre-diabetes
(IFG and IGT) NDD
n 1,710 258 220
Age (years) 37  12 43  13* 45  11*
BMI (kg/m
2) 22.6  4.0 24.2  3.5* 24.2  3.1*
Waist circumference (cm) 81.6  11.4 86.9  10.3* 88.5  9.0*
Systolic blood pressure (mmHg) 115  16.3 126.4  19.9* 128.2  21.2*†
Diastolic blood pressure (mmHg) 72.7  10.8 77.4  11.4* 78.8  11.6*
Fasting plasma glucose (mmol/l) 4.6  0.4 5.2  0.8* 8.6  3.3*†
2-h postload plasma glucose (mmol/l) 5.5  1.1 8.8  1.0* 15.5  3.7*†
A1C (%) 5.5  0.4 5.9  0.6* 8.3  2.0*†
Serum cholesterol (mmol/l) 4.5  0.9 4.8  1.0* 5.0  0.9*
Serum triglycerides (mmol/l) 1.2  0.7 1.6  1.0* 2.1  1.4*†
HDL cholesterol (mmol/l) 1.1  0.2 1.0  0.2‡ 1.0  0.2*
LDL cholesterol (mmol/l) 2.8  0.8 3.0  0.9* 3.0  0.8*
Data are means  SD. *P  0.001 compared with NGT. †P  0.001 compared with IGT. ‡P  0.01
compared with IGT.
Table 2—A1C cut points with respect to diabetes, IGT, and IFG
Condition Criteria n (%) A1C (%)
Optimal A1C
cut point Sensitivity Speciﬁcity PPV NPV AUC Accuracy
Diabetes 2-h PG 200 mg/dl or FPG
126 mg/dl (10)
225 (10.3) 8.3  2.0 6.1 88.0 87.9 45.5 98.5 0.941 90.2
Diabetes 2-h PG 200 mg/dl (10) 220 (10.1) 8.3  2.0 6.1 88.6 87.8 44.8 98.6 0.944 90.5
Diabetes FPG 126 mg/dl (10) 134 (6.1) 9.2  1.9 6.4 93.3 92.3 44.2 99.5 0.966 95.5
Diabetes 2-h PG 200 mg/dl and FPG
126 mg/dl (10)
122 (5.6) 9.2  1.6 6.5 92.6 93.7 46.3 99.5 0.978 95.9
IGT 2-h PG  140 mg/dl and
200 mg/dl (10)
248 (12.6) 5.9  0.6 5.6 65.6 62.1 19.9 92.6 0.708 74.1
IFG (WHO) FBG 110 mg/dl and 126
mg/dl (10)
10 (0.6) 5.7  0.3 5.6 60.0 56.5 0.8 99.6 0.632 69.9
IFG (ADA) FBG 100 mg/dl and 126
mg/dl (11)
83 (4.8) 5.8  0.5 5.6 65.1 63.4 8.3 97.3 0.708 70.0
Data are means  SD. AUC, area under the curve; FBG, fasting blood glucose; NPV, negative predictive value; PG, plasma glucose; PPV, positive predictive value.
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between A1C and risk of future compli-
cations (retinopathy) from western popu-
lations. Our data from an Asian Indian
population, based on the normative dis-
tribution of A1C and on its receiver oper-
ator characteristics compared with the
gold standard test (OGTT), indicates that
the A1C cut point appropriate for diag-
nosing diabetes may be different for non-
western populations. Our data suggest an
optimal A1C cut point of 5.6% in Asian
Indians to identify IGT or IFG, which are
considered to be pre-diabetes states, and,
therefore, to target groups for diabetes
prevention. The differences in A1C cut
points in different populations could be
due to potential racial and ethnic differ-
ences (17–19). Other factors such as ag-
ing, hemoglobin glycation (17,18,20),
and/orerythrocytesurvival(17,18,21,22)
could affect the A1C assay in addition to
heritable factors (23).
The advantages of the A1C test are
that it can be measured at any time of the
day with a small sample of blood and that
it also does not require the cumbersome
glucose load. The disadvantages are the
difﬁculty in standardization, cost, and
the fact that A1C cannot be measured in
the presence of hemoglobin variants (6).
The International Expert Committee
suggests a cut point of 6.0% only as an
indication for high-risk pre-diabetes
states but not as a strict cutoff point. Be-
cause there is now strong evidence that
lifestyle management of those with IGT
can reduce the rate of progression to dia-
betes (24), it is important to correctly
identify those with pre-diabetes so that
prevention efforts may be implemented,
without missing those who would beneﬁt
from intervention. Our data suggest that
despiteoptimalspeciﬁcityandsensitivity,
the A1C cut point of 5.6% only has 69–
74% accuracy of identifying IGT or IFG.
The cut point would have to be as low as
5% to identify 97% of all IGT and/or IFG.
One of the strengths of this study is
that it is population-based and from an
Asian Indian population, an ethnic group
that has a high susceptibility to type 2
diabetes. Another advantage is the high
response rates: 90% of the subjects par-
ticipated in phase 3 of CURES, of whom
A1C could be measured in 93.1%. Thus,
it is unlikely that there is any signiﬁcant
selectionbias.Onelimitationofourstudy
is that because it is cross-sectional, we
cannot assess the ability of A1C to predict
future diabetes or its micro- and macro-
vascular complications. Our focus, how-
ever, was to evaluate A1C as a screening
and diagnostic tool to identify NDD or
IGT or IFG. Although diabetes was newly
diagnosed in the subjects in the present
study, many had high glycemic and A1C
values as shown in Fig. 2. Had the diag-
nosis been made earlier, the cut points
would perhaps not have been so clear-cut
or accurate.
In summary, our population-based
data indicate that for Asian Indians a A1C
value of 6.0% may be optimal for diag-
nosing diabetes with a very high level of
accuracy. On the other hand, use of even
a cut point as low as 5.6% may miss a
Table 3—Proportion of subjects with NGT, IGT, and/or IFG and type 2 diabetes identiﬁed
using different A1C cut points
A1C cut
points NGT
Subjects with IGT and/or IFG
NDD
Using ADA
criteria
Using WHO
criteria
4.5 1,621 (99.0) 257 (99.6) 329 (99.4) 224 (99.6)
5.0 1,490 (91.0) 249 (96.5) 320 (96.7) 223 (99.1)
5.5 890 (54.3) 205 (79.5) 264 (79.8) 220 (97.8)
5.6 733 (44.7) 190 (73.6) 241 (72.8) 218 (96.9)
5.7 599 (36.6) 167 (64.7) 216 (65.3) 213 (94.7)
5.8 463 (28.3) 154 (59.7) 200 (60.4) 213 (94.7)
5.9 350 (21.4) 136 (52.7) 177 (53.5) 208 (92.4)
6.0 244 (14.9) 121 (46.9) 156 (47.1) 203 (90.2)
6.1 171 (10.4) 110 (42.6) 142 (42.9) 202 (89.8)
6.2 124 (7.6) 90 (34.9) 116 (35.0) 198 (88.0)
6.3 91 (5.6) 71 (27.5) 90 (27.2) 191 (84.9)
6.4 62 (3.8) 57 (22.1) 68 (20.5) 184 (81.8)
6.5 49 (3.0) 50 (19.4) 60 (18.1) 176 (78.2)
Data are n (%).
Figure 2—A1C distribution among subjects with NGT, IGT, and NDD. F, normal glucose tolerance; f, impaired glucose tolerance; Œ, diabetes.
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high risk of diabetes who would beneﬁt
from proven prevention interventions.
Althoughtherearemeritsforasimpleand
convenient test such as A1C to screen for
and diagnose diabetes and/or high-risk
states (such as IGT and/or IFG), it is im-
portant that proposals for cut points to
deﬁne diabetes and high-risk states take
into account population differences in
A1C levels and for this, more studies are
clearly needed in nonwestern popula-
tions. Thus, there is a need for more stud-
ies, including the cost-effectiveness of
A1Cversusplasmaglucosetesting,before
A1C can be universally recommended as
a diagnostic test for diabetes in develop-
ing countries. The recommendation for
A1C to diagnose high-risk states is even
less clear. Moreover, recognition of indi-
viduals with a high risk of diabetes can be
made on criteria other than glucose regu-
lation only; for example, overweight, in-
creased waist circumference, or other
elements of the metabolic syndrome,
which can help to identify individuals
who would need lifestyle modiﬁcation
advice. Indeed, an Indian Diabetes Risk
Score was shown to be very effective to
screen not only for undiagnosed diabetes
but also for metabolic syndrome and cor-
onary artery disease and is one of the
strongest predictors of incident diabetes
in an Asian Indian population (25).
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